Backs FY25 adjusted EBITDA view $150M-$200M.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions Reports 656% Net Income Surge
- Emergent BioSolutions Stockholders Elect Directors at Meeting
- Emergent BioSolutions announces $65M agreement to provide Ontario with NARCAN
- EBS Upcoming Earnings Report: What to Expect?
- Emergent Biosolutions: Strategic Share Repurchase and Diversified Revenue Streams Signal Strong Buy Opportunity